Angiotensin II (Ang II) promotes growth of vascular smooth muscle cells in vitro. Consistent with this, Ang II enhances neointimal proliferation in vivo after vascular injury, while angiotensin converting enzyme (ACE) inhibitors attenuate this process. Since tissue ACE plays a key role in the control of local Ang II production, we examined whether vascular injury resulted in an increase in vascular ACE expression that may result in increased Ang II production. Abdominal aorta of Sprague-Dawley rats were injured with a 2 French balloon catheter. Morphometrical changes, ACE enzymatic activity, and localization of ACE by immunohistochemistry in injured and uninjured aorta were analyzed. Vascular ACE activity in the injured aorta was significantly higher than in the uninjured aorta, while serum and lung ACE levels were not different between the two groups. The cellular distribution of the ACE protein in the neointima was similar to that of alpha smooth muscle actin but differed from those of endothelial (von Willebrand factor) or monocytes/macrophages (ED-1) markers, demonstrating that ACE was expressed in neointimal smooth muscle cells. These data demonstrate that vascular injury results in the induction of vascular ACE and suggest that the inhibition of vascular ACE may be important in the prevention of restenosis after balloon injury.
Introduction
Restenosis after percutaneous transluminal balloon angioplasty remains the major factor limiting favorable long-term outcome of many patients undergoing this procedure for coronary or peripheral vascular disease. The pathological process responsible for restenosis is neointimal hyperplasia, which is a fibroproliferative lesion consisting of intimal smooth musclelike cells, fibroblasts, and fibrous connective tissue (1, 2) . Based on experimental studies, the pathobiological events in response to vascular injury have been described. These include endothelial damage, platelet activation with release of biologically active mediators, medial smooth muscle replication with subsequent migration into the subintimal region, and neointimal cellular proliferation with matrix modulation. Several cytokines and growth factors released by activated platelets or damaged vascular cells have been implicated in the initial events.
Recent data suggest that angiotensin II (Ang II1)' may play an important role in the development of the neointimal lesion in animal models. In vitro, Ang II has been shown to stimulate vascular smooth muscle growth and migration (3) (4) (5) (6) (7) (8) . In vivo, continuous infusion of Ang II enhanced markedly vascular smooth muscle cell (VSMC) proliferation in the injured rat arterial wall (9) . Powell et al. (10) reported that angiotensin converting enzyme (ACE) inhibitors can prevent neointimal proliferation after balloon injury in rats. This effect of ACE inhibitors on experimental restenosis is due, in part, to the blockade of Ang II production, since the angiotensin receptor antagonist, DuP 753, has also been shown to be similarly effective in preventing neointimal hyperplasia (1 1, 12) . However, the increase in bradykinin after ACE inhibition may also play a role (13, 14) .
Ofpathophysiologic importance is an understanding ofthe origin of vascular Ang II that is responsible for this VSMC response. Ang II can originate from the circulation or can be synthesized locally by endothelial ACE. Since the endothelium is denuded at the site of injury, vascular Ang II must be synthesized by nonendothelial cells in the lesion or taken up actively from the circulation. Previous reports have demonstrated that pretreatment with an ACE inhibitor (cilazapril) 6 d before the injury resulted in more pronounced attenuation of neointimal formation compared with treatment initiated 2 d before or at the time of injury (10) . Furthermore, a higher dose of cilazapril was required to inhibit lesion development. It has also been shown that suppression of tissue ACE activity requires longer term or higher dose treatment with ACE inhibitor than that required for the suppression of circulating ACE activity (15) (16) (17) . Taken together, these results suggest that local tissue ACE, as opposed to serum ACE, may play a key role in the neointimal formation after balloon injury. However, the source ofthe tissue ACE in the endothelial denuded injured vessel is unknown. These studies were performed to examine the level of expression and the localization of ACE within the vessel wall during neointimal proliferation in response to balloon injury.
Our experiments demonstrate that the neointima that forms in response to vascular injury contains high levels ofimmunoreactive ACE and ACE activity. This local increase in ACE activity may be important in enhancing Ang II production and/or bradykinin degradation in the lesion. Moreover, ACE may play an important role in the pathophysiology of neointimal hyperplasia and in determining the efficacy of ACE inhibitor in the prevention of restenosis.
Methods
Preparation of arterial injury model. Male Sprague-Dawley rats weighing 500-550 g were used. Endothelial denudation and injury to the vascular wall ( 18) ( 10, 19) .
Morphometric analysis. Rats were anesthetized and blood was withdrawn from the ascending aorta via the left ventricle. The rats were then perfused at a pressure of 110 mmHg through the ascending aorta with 100 ml of PBS (pH 7.2), followed by 80 ml of freshly prepared PBS containing 4% paraformaldehyde. The abdominal aorta was removed from the branch of the left renal artery to the aortic bifurcation and cut into three portions (proximal, mid, and distal). The tissue was postfixed in the same fixative as above at 4VC for 4 h and then embedded in paraffin. The mid-portion ofthe abdominal aorta was used for the morphometric analysis.
To estimate the size ofthe intimal lesion, multiple five micron cross-sections of each vessel were stained with hematoxylin and eosin, photographed under low power, and projected onto a screen. The lesion and the vessel wall were traced carefully using a digitizing tablet (2200; Sothern Micro Systems, Atlanta, GA), and the cross-sectional areas of the neointima and the media were calculated.
Measurement of renin and ACE activities. Plasma renin activity was assayed by Ang I generation using radioimmunoassay (New England Nuclear Research Products, Boston, MA). Serum and tissue ACE activities were determined using a fluorometric assay modified from that described by Cheung and Cushman (20) . This assay measures the generation of His-Leu from a hippuryl-His-Leu (Sigma Chemical Co., St. Louis, MO). Serum or homogenized vessels were incubated for 15 min at 37°C, pH 7.5, in the presence of hippuryl-His-Leu. To measure background fluorescence, samples were incubated with no added substrate. The reaction was stopped by the addition of NaOH, pH 8.5, and the His-Leu was tagged with 0.1% phthaldealdehyde (Sigma Chemical Co.) and quantitated fluorometrically at an excitation wavelength of 386 nm and emission wavelength of 436 nm. The sensitivity ofthis assay is < 0.1 nmol/tube and the generation of His-Leu is linear from 0.1 to 13 nmol/tube. ACE activity in the aorta was calculated as nmoles His-Leu generated per minute per milligram tissue weight (Fig. 1) or per milligram protein (Fig. 2) . Protein was measured by a protein assay system (Bio-Rad Laboratories, Richmond, CA) (21 ) . ACE activity in the plasma was calculated as the nmoles His-Leu generated per minute per milliliter of plasma.
For the quantitation of the ACE in the intimal and/or medial smooth muscle cells ofthe injured and noninjured abdominal aorta, rats were anesthetized and perfused through the ascending aorta with either cold PBS or cold distilled water to remove endothelial cells. As previously reported (22) (24) , was purchased from Affinity Bioreagents (Neshanic Station, NJ). Rabbit anti-human factor VIII-related antigen polyclonal antibody, purchased from Dako Laboratory (Santa Barbara, CA), was used as an endothelial cells marker. Mouse anti-a smooth muscle actin mAb, purchased from Sigma Chemical Co., was used as the specific marker of the smooth muscle cells. Mouse anti-rat monocytes/macrophages mAb (ED-1) (25) was purchased from Chemicon International (Temecula, CA).
The processing oftissue and the preparation ofthe sections were the same as for the morphometric analysis. 5-,um sections were cut on a rotary microtome and placed on glass slides that had been treated for 20 s with acetone containing 2% 3-aminopropyltriethoxysilane (Sigma Chemical Co. Values are mean±SEM. PRA, plasma renin activity; ACE, angiotensin converting enzyme activity. Intergroup differences were not statistically significant.
Results
We have previously demonstrated that the rat abdominal aorta responds to balloon injury in a manner similar to the carotid artery (29) . At 14 d postinjury, a neointimal lesion is present that is asymmetric. The area of this lesion is -35% of the medial area, while the area ofthe media does not change significantly from the uninjured vessel. To investigate the role of the renin angiotensin system in the lesion formation, quinapril (10 mg/kg per d) was administered from 6 d before to 14 d after injury. As previously reported for the carotid injury ( 10, 19) , ACE inhibition therapy resulted in a 50% decrease in neointimal formation (Table I) . We next examined ifthe renin angiotensin system was activated in the balloon injured animal. As shown in Fig. 1 and Table II , the plasma renin activity, as well as the serum and lung ACE activities, were not altered after injury. In contrast, the injured aorta exhibited a twofold increase in ACE activity (Fig. 1) . We studied the effect of 2-wk quinapril treatment on the inhibition ofserum, lung, and vascular ACE, and observed differential responses. In response to treatment, serum ACE was completely inhibited and lung ACE was inhibited -90%. However, vascular ACE was inhibited by only 60%, even at high ACE inhibitor dose (50 mg/kg per d). At this dose, neointimal formation was also attenuated by 60% (data not shown). Figure 3 . Localization of ACE in injured and control aortae. Aortas from control rats or rats who sustained a balloon injury 2 wk previous were analyzed for ACE using a polyclonal antibody raised against human ACE (A-E) or a mAb raised against rat ACE (F-I). Control uninjured vessels exhibited staining primarily of the endothelial cells (A). This staining could be blocked by prior incubation of the antibody with purified human ACE (B). Injured vessels exhibited neointimal staining and some diffuse medial staining (C). Preabsorption of the antisera with purified ACE again abolished the immunohistochemical staining (D). Nonimmune rabbit serum was also negative (E). A similar distribution was ob served in the uninjured (F) and injured (G) when a mAb against rat ACE was used. This staining was specific since no signal was seen in either vessel when a control IgM was used (H and I).
The increase in vascular ACE in response to injury was not due to regenerated endothelial cells (Fig. 2) . Water perfusion, which removes endothelial cells (as documented immunochemically), has no effect on the ACE activity in the injured aorta. Similar treatment of the uninjured aorta reduced ACE activity by > 50%. Thus, the injured vessel expressed significantly higher ACE activity than that seen in the uninjured vessel, and this ACE activity is contained in nonendothelial layer(s).
To identify more precisely the cells that contain ACE, we performed immunohistochemical analysis using a rabbit polyclonal antibody raised against human ACE (Fig. 3, A-E) . Rakugi et al. dothelial cells were identified with antibody raised against vWF (Fig. 4, A and B) , smooth muscle cells were identified with an antibody raised against alpha smooth muscle actin (Fig. 4 C) , and monocytes and macrophages were identified with an antibody raised against ED-I (Fig. 4 D) . In the control aorta, the endothelial cells, identified by positive staining for vWF (Fig. 4  A) , stained positive for ACE (Fig. 3 A) , suggesting that in the control aorta, the endothelial cells were a source of ACE activity. The staining with the antihuman ACE antibody could be blocked by prior incubation with purified human ACE (Fig. 3  B) . Under the conditions used for the immunohistochemistry, little or no staining was observed in the medial layers. In the balloon-injured aorta, the neointimal layer stained intensely with the ACE antibody (Fig. 3 C) . This staining colocalized with staining for alpha smooth muscle actin (Fig. 4 C) but not with staining for monocytes and macrophages (Fig. 4 D) , suggesting its presence in the neointimal smooth muscle cells. As above, the staining in the medial layers was much less than that observed in the neointima. In some sections, patchy areas of endothelial cells staining positive for vWF could be observed on the luminal surface of the neointima (Fig. 4 B) , suggesting that endothelial cells contributed, to a small degree, to the ACE activity found in the balloon-injured vessel wall. No staining was observed when the ACE antibody was replaced with control rabbit serum (Fig. 3 E) .
Similar results were observed when an anti-rat ACE mAb was used (Fig. 3, F-I ). Using this mAb, intense staining ofthe endothelial layer was observed in the control vessel (Fig. 3 F) . In the balloon-injured vessel, intense staining was observed in the neointimal layer (Fig. 3 G) . In both the control and balloon-injured vessels, only weak, diffuse staining was observed in the medial layers. No detectable staining was observed in the media or in the neointima when the antibody was substituted with a control ascites fluid (Fig. 3, H-I) .
These results suggest that the neointima contains ACE activity. We performed an additional experiment to address this issue directly. A group of rats underwent balloon injury of the aorta. At 2 wk postinjury, the injured aortae were removed. One group of vessels were perfused with PBS to wash off contaminating serum. A second group of vessels were perfused with cold water to remove the endothelial cells (22) , and a third group of vessels were scraped with a Q-tip to remove the neointima. Aortae from rats that had not undergone balloon injury were treated similarly. The vessels were then assayed for ACE activity. As shown in Fig. 2 , the ACE activity of cold water perfused vessels was not significantly different from that of PBS perfused vessels. Scraping decreased the aortic ACE activity by 40% (7.13±0.68 nmol/min per mg protein [ Figure 4 . Cell type identification in the injured aortae. Endothelial cells in the uninjured (A) and injured (B) aorta were localized using a polyclonal antibody raised against vWF. The staining in both vessels was restructured to the luminal endothelial cells. Smooth muscle cells in the injured vessel were localized with an antibody against alpha smooth muscle actin (C). Monocytes and/or macrophages in the injured vessel were identified with an ED-l-specific antibody (D) . No staining was evident when a nonimmune rabbit serum was used (E). In all panels, the lumen is at the top. 
Discussion
The results of this study demonstrate that vascular injury increases ACE activity in the neointima. Our data may explain the mechanism of ACE inhibitor's action in the prevention of restenosis after balloon injury. A key to the understanding of the role of renin angiotensin in neointimal proliferation is to identify the origin of vascular ACE after injury. With the removal of the endothelium, circulating ACE could become accessible to VSMC. However, in experiments of chronic quinapril treatment, we observed a dissociation between circulating and vascular ACE activities. While serum ACE activity was completely inhibited in the quinapril-treated rats, vascular ACE activities in uninjured or injured aorta were only inhibited by 60%. 344 Our immunohistochemical data suggest that the cells containing ACE are primarily smooth muscle-like cells, as identified by positive costaining with a smooth muscle actin antibody. Although monocytes are known to express ACE (30, 31 ) , our immunostaining data demonstrated that only a few cells in the rat neointima stained positive for the macrophage marker, ED-1, and therefore cannot account for the robust ACE immunoreactivity in many cells in the lesion. The regenerated endothelial cells could be considered as another source ofACE after injury, since we noted positive immunohistochemical staining with vWF on the luminal layer of the neointima. However, the staining was patchy and could only account for a few ACE-positive cells. Furthermore, the removal of endothelial cells by water perfusion did not change ACE activity in the injured vessels. These results suggest that the contribution of regenerated endothelial cells to the increased ACE activity in injured vessels is relatively small. Taken together, our data indicate that after vascular injury the proliferating neointimal smooth muscle cells contain high levels of immunoreactive and enzymatically active ACE.
The residual ACE activity in the uninjured vessel after endothelial removal (via cold water perfusion) as well as the diffuse, low level of specific immunoreactivity (especially with the anti-rat mAb) in the medial layer ofboth the injured and uninjured vessel, suggest that the medial layer contains ACE. Immunohistochemical analysis suggests that the content on a per unit area (roughly equivalent to a per cell basis) is much higher in the neointima than in the media. However, the current data do not allow a more accurate assessment of the relative per cell expression of ACE in the medial and neointimal regions nor does it allow an assessment ofthe effects ofinjury on the medial expression of ACE. At 2 wk after injury, the neointima represents only 25% of the total area of the injured vessel (Table I) , whereas the ACE activity in the injured vessel is threefold higher than in the deendothelialized (cold water perfused) noninjured vessel (Fig. 2) . While there is no apparent increase in immunoreactivity in the medial region of the injured vs. the uninjured vessel, quantitation by immunohistochemistry is not accurate. Physical scraping of the neointima decreased the ACE activity in the injured vessel by 40%, but this is a minimum estimate of the contribution of neointimal ACE to total vascular ACE since these scraped vessels contained residual neointima. Therefore, the most consistent and accurate interpretation is that the increase in vascular ACE activity after injury may be due both to an increase in medial ACE expression as well as the development of a neointima that, on a per cell basis, contains much higher levels of ACE.
Similarly, the area ofthe endothelial layer in the uninjured vessel is several orders of magnitude lower than that of the media, yet the endothelial layer contains -50% of the ACE activity (Fig. 2) . Thus, on a per unit area basis, the quantity of ACE in the endothelial cells is many-fold higher than in the medial layer.
Previous studies demonstrated that neointimal smooth muscle cells exhibit many of the characteristics of neonatal smooth muscle cells. The data ofSchwartz and coworkers (32) (33) (34) suggest that the neointimal and neonatal smooth muscle cells may be of the same lineage. Thus, the expression of ACE in the neointimal smooth muscle cells is consistent with the concept that these cells originate from a select population or assume a fetal phenotype in response to injury. Indeed, our preliminary data that cultured neonatal smooth muscle cells express ACE provide further support for this hypothesis (35) .
Based on the in vitro and in vivo effects of Ang II on smooth muscle migration and proliferation (3) (4) (5) (6) (7) (8) (9) , one might conclude that the action ofACE inhibition is the result ofinhibition of Ang II production. Indeed, recent data have demonstrated that the AT-l receptor antagonist, Dup 753, can also prevent the neointimal formation in the rat carotid artery ( 11, 12) or abdominal aorta (Rakugi, H., and R. E. Pratt, unpublished data). Moreover, Ang II infusions can overcome the blockade of lesion development by ACE inhibitors ( 11) . The inhibition of ACE-mediated kinin degradation may also contribute to the growth inhibitory action of ACE inhibitors since it has been shown that HOE 140, a kinin receptor antagonist, can blunt the inhibitory effects of ramapril on neointimal formation ( 13, 14) . In the intact vessel, kinins may act indirectly via the stimulation ofendothelial-dependent vasodilators such as endothelial-derived relaxing factor and prostaglandins (36, 37 The high concentration of ACE in the developing lesion may play an important role in the pathogenesis of neointimal hyperplasia leading to restenosis after vascular injury. This and other studies ( 10, 19) have demonstrated that ACE inhibitors (quinapril, cilazapril, ramapril, and captopril) can attenuate the neointimal formation after balloon injury in the rat. ACE inhibitors can also inhibit neointima formation in response to injury in the guinea pig (38) , and attenuate allograft-induced intimal formation in the rat (39). In the rat carotid injury model, we have shown that the level of vascular ACE activity correlated with the severity of the lesion, suggesting a causal relationship (Rakugi, H., D. Wang, V. J. Dzau, and R. E. Pratt, manuscript submitted for publication). Recent evidence also suggests that ACE inhibitors can inhibit the development of atherosclerosis in Watanabe rabbits (40) or cholesterol fed primates (41 ) , and can inhibit the migration of monocytes into the vessel wall (42) . On the other hand, species-specific differences in the response to ACE inhibitors appear to exist since cilazapril does not inhibit neointimal development in the balloon-injured baboon (43) . The relevance ofthese animal studies to human restenosis is being addressed by a number of clinical studies. The early results from the MERCATOR and MARCATOR clinical trials suggest that the ACE inhibitor, cilazapril, does not inhibit angiographic restenosis (44, 45) . However, the protocol design of these two trials is significantly different from that of the animal studies. For example, data from studies using the balloon-injured rat carotid artery demonstrated that the inhibition of tissue ACE activities requires the higher dose or longer term pretreatment with ACE inhibitors ( 13-15). In the MERCATOR and MARCATOR trials, the patients were administered a "low" dose of the ACE inhibitor (1 /10 and 1 /5 of the effective dose in animal dose, respectively) immediately after percutaneous transluminal coronary angioplasty (PTCA) (in contrast to 7 d before experimental vascular injury). While species specific differences in the response of an injured vessel to ACE inhibitor treatment may be an explanation, further clinical studies using an effective drug concentration for an appropriate duration before PTCA are needed to test the hypothesis in humans. Taken together, our finding that ACE is expressed in the neointimal lesion suggests further that the effective inhibition of tissue ACE may be a critical determinant of the prevention of restenosis after balloon angioplasty.
